Meeting slides
Interactive presentation
Scientific Insights Into Incretin Signaling and Type 2 Diabetes
Jack L. Leahy, MD
Suggested Readings
Standards of Medical Care in Diabetes-2012.
American Diabetes Association. Diabetes Care. 2012;35:S11-S63.
Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action.
Campbell JE, Drucker DJ. Cell Metab. 2013;17:819-837.
AACE Comprehensive Diabetes Management Algorithm.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. 2013. Endocr Pract. 2013;19:327-336.
Novel Therapies for the Management of Type 2 Diabetes Mellitus: Part 2. Addressing the Incretin Defect in the Clinical Setting in 2013.
Grunberger G. J Diabetes. 2013;5:241-253.
Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes.
Holst JJ, Knop FK, Vilsboll T, Krarup T, Madsbad S. Diabetes Care. 2011;34 (suppl 2):S251-S257.
Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database.
Horton ES, Silberman C, Davis KL, Berria R. Diabetes Care. 2010;33:1759-1765.
Exenatide Once Weekly: Sustained Improvement in Glycemic Control and Cardiometabolic Measures Through 3 Years.
Macconell L, Pencek R, Li Y, Maggs D, Porter L. Diabetes Metab Syndr Obes. 2013;6:31-41.
Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes.
Scheen AJ. Postgrad Med. 2013;125:7-20.
The Role of Co-morbidity in the Selection of Antidiabetic Pharmacotherapy in Type-2 Diabetes.
Tschope D, Hanefeld M, Meier JJ, et al. Cardiovasc Diabetol. 2013;12:62.
Blood Pressure-Lowering Effects of GLP-1 Receptor Agonists Exenatide and Liraglutide: a Meta-Analysis of Clinical Trials.
Wang B, Zhong J, Lin H, et al. Diabetes Obes Metab. 2013;15:737-749.